SRP404201 PRJNA893589 GSE216418 In Vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in Human Chordoma Xenografts [RNA-seq] We evaluated the tumor efficacy of the CDK4/6 inhibitor palbociclib in two chordoma Patient's Derived Xenograft (PDX) models to validate and identify novel therapeutic approaches. Overall design: Gene expression analysis of RNA-seq data for two chordoma PDX models (CD3 and CD7), without treatment and after palbociclib treatment. GSE216418 pubmed 36505864 parent_bioproject PRJNA893580